Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market

Transcription

1 A Datamonitor report Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market Published: Oct-06 Product Code: DMHC2223 Providing you with: Diagnosis patterns of NSCLC including stage distribution and extent of resectability based on a survey of 180 physicians across the seven markets Analysis of treatment modalities and regimens according to Datamonitor's primary research data Ranking of the greatest areas of unmet need within the NSCLC market Use this report to... Identify the key factors that influence prescribing patterns for NSCLC pharmacotherapy Physician ratings of key pipeline NSCLC candidates and the likelihood of future scenarios occurring

2 Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market DMHC2223 Introduction NSCLC comprises over 75 per cent of all lung cancers. In, more than 338,000 cases of the disease are expected to be diagnosed in the seven major pharmaceutical markets. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient's remains below 12 months. Cytotoxic drugs form the mainstay of NSCLC therapy but are associated with a spectrum of adverse effects such as nausea and vomiting, alopecia, cardiotoxicity and neuropathy. However, molecular targeted therapies (MTTs) directed against a broad range of molecular aberrations are set to transform the market, offering improved efficacy and toxicity profiles. OSI/Genentech/Roche's Tarceva (erlotinib) is already FDA and EMEA approved for refractory NSCLC, and Genentech/Roche's Avastin (bevacizumab), recently gained FDA approval as the first MTT for first-line NSCLC therapy. Key findings and highlights According to Datamonitor's research, one-third of all non-resectable advanced NSCLC patients receive no drug therapy. The development of agents suitable for elderly and poor performance status patients, inducing those with existing comorbidities, provides significant commercial opportunity. While platinum-based regimens form the mainstay of first-line NSCLC treatment, Datamonitor's research reveals that there is little to differentiate between the available cytotoxic regimens, indicating that the efficacy of cytotoxics may have reached a plateau. Avastin has become the first FDA approved MTT for the first-line treatment of NSCLC, labelled for administration in combination with carboplatin and paclitaxel. As more MTTs emerge from the developmental pipeline and targeted patient selection becomes more frequent, the treatment of NSCLC will undergo a transformation. Reasons to buy Identify the key factors that influence prescribing patterns for NSCLC pharmacotherapy Examine the significant unmet needs in the NSCLC market and identify opportunities for new product development Enhance your commercial positioning through an increased understanding of NSCLC market dynamicst For more information... Contact Joanna Chertkow, 21C Analysis Team tel: fax: hcmarketing@datamonitor.com

3 Sample pages from the report...i think that there are probably 90 per cent of practicing oncologists within my country that prescribe carboplatin-based regimens rather than cisplatin-based regimens. Carboplatin-based regimens are the standard within my country... Key opinion leader, Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market

4 Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market DMHC2223 Table of contents ABOUT DATAMONITOR HEALTHCARE About the Oncology pharmaceutical analysis team EXECUTIVE SUMMARY Scope of the analysis Datamonitor insight into the NSCLC market INTRODUCTION AND SCOPE Coverage of the Stakeholder Insight Survey - Disease definition & epidemiology - Diagnosis - Resectable disease - Non-resectable disease - Drug regimens - Unmet needs - Future focus COUNTRY TREATMENT TREES US Japan France Germany Italy Spain UK DISEASE DEFINITION AND EPIDEMIOLOGY Lung cancer is divided into two major subtypes according to its biology, therapy and prognosis - Non-small cell lung cancer accounts for more than 75% of all lung cancers - Three major histological subtypes of NSCLC exist Epidemiology of NSCLC - The NSCLC death rate now exceeds that of breast, prostate and colon cancers combined SEGMENTING THE NSCLC POPULATION Segmentation of NSCLC is usually based on the AJCC's TNM staging system - Over half of all NSCLC patients across the seven major markets are diagnosed in the advanced stages Extent of resection across the seven major markets - Surgical resection offers a cure but the greatest benefit is restricted to early-stage NSCLC Resectable versus non-resectable disease - The general trend across the major markets shows that suitability for curative surgery diminshes as disease stage advances TREATMENT OF RESECTABLE DISEASE The use of drug therapy in combination with surgery - Data from Phase III neo-adjuvant clinical trials is limited - Adjuvant therapy historically showed negative results and was associated with stigma... - Combination of neo-adjuvant and adjuvant chemotherapy show favorable results Chemotherapy approaches vary across the four major stages of NSCLC - Physicians prefer to use combined neo-adjuvant and adjuvant chemotherapy across the seven major markets for stage I/II resectable patients... - Minimal differences are found in the prescribing of neo-adjuvant and adjuvant chemotherapy between stages IIIA and IIIB... - Combined neo-adjuvant and adjuvant treatment is prescribed most frequently for resectable stage IV NSCLC Chemotherapy approaches by disease stage - With advancing stage of disease physicians switch from adjuvant chemotherpay alone to combined neo-adjuvant and adjuvant approaches - The use of drug therapy is reduced in patients with advanced disease TREATMENT OF NON-RESECTABLE DISEASE Increasing use of chemotherapy with advancing disease in non-resectable NSCLC - Early stage non-resectable patients are ideal candidates for radiotherapy Use of chemotherapy treatment for non-resectable patients shows little variation at market level - US and German physicians take an aggressive approach to chemotherapy treatment of nonresectable stage IV patients For more information... Contact Joanna Chertkow, 21C Analysis Team tel: fax: hcmarketing@datamonitor.com

5 CURRENT DRUG REGIMENS Current first-line NSCLC drug regimens - Single, doublet and triplet chemotherapy regimens by disease stage - Single, doublet and triplet chemotherapy regimens by market - Platinum-based regimens by disease stage - Platinum-based regimens by market - Use of platinum-taxane doublets versus platinumnon-taxane third-generation cytotoxic doublet regimens by disease stage The top three first-line NSCLC drug regimens by disease stage - Carboplatin-paclitaxel is the leading drug-regimen in first-line NSCLC - The top three first-line drug regimens by market - Carboplatin-paclitaxel is still at the forefront of firstline stage IV treatment, but only within three markets - Single-agent regimens by disease stage - Molecular targeted therapeutics versus cytotoxics by disease stage - Molecular targeted therapeutics versus cytotoxics by market - Iressa-, Tarceva-, Avastin- and Erbitux-based regimens by disease stage - First-line use of Iressa-, Tarceva-, Avastin- and Erbitux-based regimens by market Current second-line NSCLC drug regimens - The leading second-line NSCLC drug regimens currently used by physicians across the seven major markets Current third-line NSCLC drug regimens - The leading third-line NSCLC drug regimens currently used by physicians across the seven major markets Current NSCLC drug regimens by line setting - Platinum-based regimens by line setting - Molecular targeted therapeutics versus cytotoxic therapy by line setting - Iressa-, Tarceva-, Avastin- and Erbitux-based regimens by line setting The impact of Alimta and Tarceva on current Taxotere prescribing - First-line prescribing of Taxotere-platinum doublet has reached a plateau - Tarceva's ability to improve progression-free surival renders the agent a significant threat to Alimta and Taxotere in the second-line setting of NSCLC UNMET NEEDS Physician rating of clinical unmet needs within the NSCLC market Unmet needs within today's NSCLC market - With just 15 per cent of NSCLC patients surviving beyond five years, effective agents that improve survival are needed - Earlier diagnosis of NSCLC could improve patient prognosis - Virtually all NSCLC patients relapse following firstline chemotherapy - Opportunity for a first-line agent with reduced toxicity - Cost-effective molecular targeted therapies are required - Despite constituting about 65 per cent of all NSCLC patients, suitable therapeutics for the elderly remain elusive - BAC and adenocarcinoma patients are underserved - Optimal patient selection is vital for successful development of targeted therapies - Analysis of NSCLC unmet needs by country POTENTIAL OF EMERGING THERAPIES Overview of the key NSCLC candidates - Genentech/Roche's Avastin (bevacizumab) is the first anti-angiogenic agent to gain approval - Erbitux (cetuximab), the EGFR monoclonal antibody, is involved in numerous ongoing NSCLC trials - Nexavar (sorafenib) is the first oral multi-tyrosine kinase inhibitor to reach the market - AstraZeneca's Zactima (vandetanib; ZD6474) targets both VEGF and EGFR - Amgen's Vectibix (panitumumab) is a fully humanized monoclonal antibody targeting firstand-second-line NSCLC Physician ratings of key pipeline NSCLC candidates - Physician ratings of the five NSCLC candidates are similar suggesting companies need to differentiate their products - Physician ratings of key pipeline NSCLC candidates by country analysis FUTURE FOCUS Perceived future drug regimen prescribing - Platinum-doublet regimens will continue to form the backbone of NSCLC treatment - Although doublet cytotoxics will remain at the forefront of future treatment of NSCLC, Avastin and Erbitux may reduce the use of platinum-triplet regimens For more information... Contact Joanna Chertkow, 21C Analysis Team tel: fax: hcmarketing@datamonitor.com

6 Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market DMHC2223 Influences on physician prescribing within the future NSCLC market - First-line combination chemotherapy is considered the most important scenario within the future NSCLC market APPENDIX A APPENDIX B APPENDIX C TABLES Table 1: NSCLC physician breakdown surveyed by Datamonitor, Table 2: Crude incidence rates of lung cancer by gender (per 100,000) in the seven major markets, 2002 Table 3: Forecast incidence of lung cancer (types C33 and C34) in the seven major markets, Table 4: Forecast incidence of NSCLC in the seven major markets, Table 5: American Joint Committee on Cancer TNM staging of NSCLC Table 6: American Joint Committee on Cancer TNM staging of NSCLC Table 7: NSCLC patients diagnosed at each stage (I-IV) (%), Table 8: Mean NSCLC patients suitable for surgery with curative intent, across the seven major markets, (%), Table 9: Stage I/II NSCLC patients suitable for surgery Table 10: Stage IIIA NSCLC patients suitable for surgery Table 11: Stage IIIB NSCLC patients suitable for surgery Table 12: Stage IV NSCLC patients suitable for surgery Table 13: Summary results of Martini et al. (1993) Phase III neo-adjuvant trial in stage IIIA NSCLC patients Table 14: Summary results of Roth et al. (1994) and Rossell et al. (1994) Phase III neo-adjuvant trials in stage IIIA NSCLC patients Table 15: Preliminary results of Pisters et al. (2005) Phase III neo-adjuvant trial in stage I-IIIA NSCLC patients Table 16: Summary of Sorensen et al. (2005) Phase III neo-adjuvant trial in stage I-IIIA NSCLC patients Table 17: Arguments for and against neo-adjuvant NSCLC chemotherapy Table 18: Summary of results of the International Adjuvant Lung Cancer Trial (IALT) Table 19: Summary of key Phase III adjuvant NSCLC trials; CALC GB 9633; NCIC CTG JBR.10 and ANITA Table 20: Arguments for and against adjuvant NSCLC chemotherapy Table 21: Arguments for and against combined neoadjuvant and adjuvant chemotherapy Table 22: Chemotherapy approaches for resectable stage I/II NSCLC patients in the seven major markets (%), Table 23: Chemotherapy approaches for resectable stage IIIA NSCLC patients across the seven major Table 24: Chemotherapy approaches for resectable stage IIIB NSCLC patients in the seven major Table 25: Chemotherapy approaches for resectable stage IV NSCLC patients in the seven major markets (%), Table 26: Mean chemotherapy approaches for resectable NSCLC patients between stages I and IV, across the seven major Table 27: Mean use of chemotherapy treatment within non-surgical NSCLC patients between stage I/II and stage IV, across the seven major markets (%), Table 28: Use of chemotherapy treatment in nonresectable NSCLC patients by stage across the seven major Table 29: Use of first-line single, doublet and triplet chemotherapy regimens for stage I/II-IV NSCLC across the seven major markets (%), Table 30: Use of first-line platinum-based regimens for stage I/II and stage IIIA NSCLC in the seven major Table 31: Use of first-line platinum-based regimens for stage IIIB to stage IV across the seven major markets (%), 2005 Table 32: Arguments for platinum-based versus nonplatinum-based regimens in NSCLC Table 33: Use of first-line platinum-taxane versus platinum-non-taxane third-generation cytotoxic regimens for the treatment of stage I/II-IV NSCLC in the seven major For more information... Contact Joanna Chertkow, 21C Analysis Team tel: fax: hcmarketing@datamonitor.com

7 Table 34: Use of the top-three first-line drug regimens for the treatment of stage I/II-IV NSCLC in the seven major Table 35: Use of first-line single-agent regimens for the treatment of stage I/II-IV NSCLC across the seven major Table 36: Use of first-line MTT-based regimens and cytotoxics for stage I/II-IV NSCLC in the seven major Table 37: Percentage use of first-line Iressa-, Tarceva-, Avastin- and Erbitux-based regimens for the treatment of stage I/II-IV NSCLC in the seven major Table 38: Use of the top three second-line drug regimens for the treatment of all stages of NSCLC in the seven major Table 39: Use of the top three third-line drug regimens for the treatment of all stages of NSCLC in the seven major Table 40: Mean use of platinum-based and non-platinumbased regimens for the treatment of all stages of NSCLC by line setting, across the seven major markets, (%), Table 41: Mean use of molecular targeted therapeutics versus cytotoxic therapy for the treatment of all stages of NSCLC, within the three line settings, across the seven major markets, (%) Table 42: Mean use of gefitinib, erlotinib, bevacizumab and cetuximab-based regimens for the treatment of all stages of NSCLC, within the three line settings, across the seven major Table 43: Mean use of Taxotere, Alimta and Tarceva within NSCLC, across the seven major markets (%), Table 44: TAX-317 and TAX-320 clinical trial results: survival data Table 45: Results of a Phase III randomized trial comparing Alimta to Taxotere in second-line treatment of recurrent NSCLC, Table 46: Summary of Tarceva's Phase III BR.21 efficacy data Table 47: Comparison of the efficacy results from pivotal trials which gained Tarceva, Taxotere and Alimta FDA and EMEA approval for second-line NSCLC Table 48: Comparison of the key toxicity results from pivotal trials which gained Tarceva, Taxotere and Alimta FDA and EMEA approval for second-line NSCLC Table 49: Physician rating of unmet needs (1-100) in NSCLC across the seven major markets, Table 50: Summary of Phase III clinical trials involving elderly advanced NSCLC patients Table 51: Preregistration and Phase III NSCLC pipeline, Table 52: NSCLC clinical trial summary: Avastin Table 53: Avastin E4599 Phase II/III clinical trial results Table 54: NSCLC clinical trial summary: Erbitux, Table 55: NSCLC clinical trial summary: Nexavar Table 56: NSCLC clinical trial summary: Zactima Table 57: Physician scoring (1-100) of the likelihood of prescribing key NSCLC pipeline drug-based regimens (1-100), in the seven major markets, Table 58: Physician scoring (1-100) of various drug regimen prescribing for NSCLC patients in 2011, across the seven major markets Table 59: Current use of first-line platinum and nonplatinum doublets, triplet regimens, signal transduction and angiogenesis inhibitors for the first-line treatment of all stages of NSCLC, across the seven major Table 60: Physician scoring (1-100) of various prescribing scenarios for NSCLC in 2011 across the seven major markets Table 61: Use of first-line drug regimens for stage I/II NSCLC, regardless of whether received as neo-adjuvant and/or adjuvant treatment, across the seven major Table 62: Use of first-line drug regimens for stage IIIA NSCLC, across the seven major markets (%), Table 63: Use of first-line drug regimens for stage IIIB NSCLC, across the seven major markets (%), Table 64: Use of first-line drug regimens for stage IV NSCLC in the seven major Table 65: Use of second-line drug regimens for the treatment of stages I/II to stage IV NSCLC in the seven major Table 66: Use of third-line drug regimens for the treatment of stages I/II to stage IV NSCLC, across the seven major FIGURES Figure 1: Diagrammatic overview of the coverage of the Stakeholder Insight: Non-Small Cell Lung Cancer survey, Figure 2: Population and chemotherapy approach data for NSCLC in the US, Figure 3: Second- and third-line NSCLC drug regimens in the US, Figure 4: Population and chemotherapy approach data for NSCLC in Japan, Figure 5: Second- and third-line NSCLC drug regimens in Japan,...I think oncologists are interested in the combination of Avastin and Tarceva and this may lead to the third-line use of these agents. There's a suggestion from a couple of trials that using Avastin and Tarceva [together] is better than the therapeutics used as monotherapy... Key opinion leader, Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market

8 Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market DMHC2223 Figure 6: Population and chemotherapy approach data for NSCLC in France, Figure 7: Second- and third-line NSCLC drug regimens in France, Figure 8: Population and chemotherapy approach data for NSCLC in Germany, Figure 9: Second- and third-line NSCLC drug regimens in Germany, Figure 10: Population and chemotherapy approach data for NSCLC in Italy, Figure 11: Second- and third-line NSCLC drug regimens in Italy, Figure 12: Population and chemotherapy approach data for NSCLC in Spain, Figure 13: Second- and third-line NSCLC drug regimens in Spain, Figure 14: Population and chemotherapy approach data for NSCLC in the UK, Figure 15: Second- and third-line NSCLC drug regimens in the UK, Figure 16: Anatomy of the human lungs Figure 17: Forecast incidence of lung cancer (types C33 and C34) in the seven major markets, Figure 18: Forecast incidence of NSCLC in the seven major markets, Figure 19: NSCLC patients diagnosed at each stage (I-IV) (%), Figure 20: Mean NSCLC patients suitable for surgery with curative intent, across the seven major markets, (%) Figure 21: Stage I/II NSCLC patients suitable for surgery Figure 22: Stage IIIA NSCLC patients suitable for surgery Figure 23: Stage IIIB NSCLC patients suitable for surgery Figure 24: Stage IV NSCLC patients suitable for surgery Figure 25: Chemotherapy approaches for resectable stage I/II NSCLC patients in the seven major markets (%), Figure 26: Change in chemotherapy approaches between stage IIIA and stage IIIB resectable NSCLC in the seven major Figure 27: Chemotherapy approaches for resectable stage IV NSCLC patients in the seven major markets (%), Figure 28: Mean chemotherapy approaches for resectable NSCLC patients between stage I/II and IV, across the seven major markets, Figure 29: Mean use of chemotherapy treatment within non-surgical NSCLC patients between stage I/II and stage IV, across the seven major markets (%), Figure 30: Use of chemotherapy treatment in non-surgical stage IV NSCLC patients in the seven major Figure 31: Mean use of first-line single, doublet and triplet chemotherapy regimens for stage I/II-IV NSCLC across the seven major markets (%), Figure 32: Use of first-line single, doublet and triplet chemotherapy regimens for stage IV NSCLC in the seven major Figure 33: Mean use of first-line platinum-based regimens from stage I/II-IV, across the seven major Figure 34: Use of key first-line drug regimens for stage IV NSCLC in the seven major Figure 35: Mean use of platinum-taxane doublets versus platinum-non-taxane third-generation cytotoxic doublets for the treatment of stage I/II-IV NSCLC, across the seven major markets (%), Figure 36: Use of first-line platinum-taxane versus platinum-non-taxane third-generation cytotoxic regimens for the treatment of stage IV NSCLC in the seven major Figure 37: Mean use of the top three first-line drug regimens for the treatment of stage I/II-IV NSCLC, across the seven major markets (%), Figure 38: Use of the top three first-line drug regimens for the treatment of stage IV NSCLC (%), Figure 39: Use of the top-three first-line drug regimens for the treatment of stage IV NSCLC (%), Figure 40: Mean use of first-line single-agent regimens for the treatment of stage I/II-IV NSCLC across the seven major Figure 41: Mean use of first-line MTT-based regimens for stage I/II-IV NSCLC across the seven major Figure 42: Use of first-line MTT-based regimens for stage IV NSCLC in the seven major markets (%), Figure 43: Mean use of first-line Iressa-, Tarceva-, Avastinand Erbitux-based regimens for the treatment of stage I/II-IV NSCLC, across the seven major For more information... Contact Joanna Chertkow, 21C Analysis Team tel: fax:

9 Figure 44: Use of first-line Iressa, Tarceva, Avastin and Erbitux-based regimens for the treatment of stage IV NSCLC in the seven major markets (%), Figure 45: Use of the top three second-line drug regimens for the treatment of all stages of NSCLC, as a mean of the seven major markets and within the US, Japan and France (%), Figure 46: Use of the top three second-line drug regimens for the treatment of all stages of NSCLC, within Germany, Italy, Spain and the UK (%), Figure 47: Use of the top three third-line drug regimens for the treatment of all stages of NSCLC as a mean of the seven major markets and within the US, Japan and France (%), Figure 48: Use of the top three second-line drug regimens for the treatment of all stages of NSCLC within Germany, Italy, Spain and the UK (%), Figure 49: Mean use of platinum-based and non-platinumbased regimens for the treatment of all stages of NSCLC within the three line settings, across the seven major Figure 50: Mean use of molecular targeted for the treatment of all stages of NSCLC, within the three line settings, across the seven major markets (%) Figure 51: Mean use of gefitinib, erlotinib, bevacizumab and cetuximab-based regimens for the treatment of all stages of NSCLC, within the three line settings, across the seven major Figure 52: Timeline of the FDA and EMEA approvals of Taxotere, Alimta and Tarceva within NSCLC, Figure 53: Mean physician rating of clinical unmet needs (1-100) in NSCLC, across the seven major markets, Figure 54: Physician rating of clinical unmet needs (1-100) in NSCLC, for the mean, the US, Japan and France, Figure 55: Physician rating of clinical unmet needs (1-100) in NSCLC for the UK, Spain, Italy and Germany, Figure 56: Mean physician scoring (1-100) of the likelihood of prescribing key NSCLC pipelinebased regimens (1-100), across the seven major markets, Figure 57: Physician rating of key NSCLC pipeline-based regimens (1-100) in the seven major markets, Figure 58: Physician scoring (1-100) of various drug regimen prescribing for NSCLC patients in 2011 in the seven major markets Figure 59: Physician scoring (1-100) of various prescribing scenarios for NSCLC in 2011 For more information... Contact Joanna Chertkow, 21C Analysis Team tel: fax: hcmarketing@datamonitor.com

10 Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market DMHC2223 Datamonitor: Your total information solution Datamonitor is a premium business information company helping 5,000 of the world's leading companies across the Automotive, Consumer Markets, Energy, Financial Services, Healthcare and Technology sectors. Our products and services are specifically designed to support our clients key business processes from corporate strategy to competitive intelligence. We provide an independent and trustworthy source of data, analysis and forecasts to improve these processes and ultimately, to help grow your business. Corporate Strategy & Business Planning Quality Data Make more effective strategic and business decisions Product Development & Commercialization Targeting & Influencing the Market Expert Analysis Accelerate delivery of commercial success Assess and influence your commercial and market environment HELPING TO GROW YOUR BUSINESS Market & Competitive Intelligence Future Forecasts Maintain or obtain critical competitive advantage Nothing speaks louder than our clients 3M Abbott Accenture Alcon Labs Allergan Almirall-Prodesfarma Altana Pharma AG Amersham Amgen Amrad Angelini Acraf Astellas AstraZeneca AT Kearney Baxter Bayer Healthcare AG Beaufour Ipsen Biochemie Biogen Idec Boehringer Ingelheim Boots Bristol-Myers Squibb Cantab Caremark International Chiesi Chiron Chugai CMC Co Daiichi Deutsche Morgan Grenfell Elan Eli Lilly Esteve Flamel Fournier Gehe Genzyme Gilead Gist Brocades GlaxoSmithKline IBM Immuno AG Johnson & Johnson Jouveinal LEK Lipha Lundbeck Merck KGaA Merck & Co Millennium Pharmaceuticals Nabi Biopharmaceuticals Novartis Novo Nordisk Pfizer Pharmachemie Pierre Fabre Pliva Procter & Gamble Ranbaxy Recordati Sankyo sanofi-aventis Schering AG Schering-Plough Schwarz Pharma AG Serono Shire Pharmaceuticals Solvay Pharmaceuticals Takeda TAP Pharmaceutical Teva UCB Uriach Vernalis Viatris Wyeth...89% of our clients use Datamonitor research to develop competitive intelligence... Source: Datamonitor Customer Research

11 Interested in this topic? Datamonitor s Oncology portfolio features detailed analysis of development pipelines, current and future market dynamics, patient potential, treatment patterns, and strategic issues, to highlight latest market trends and new commercial opportunities. - Hormonal Therapies - Innovative Therapies - Cytotoxic Therapies - Key tumor types: breast, colorectal, lung, ovarian, prostate, niche Also available in this portfolio Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline Analysis of the marketed and pipeline molecular targeted cancer therapies. Includes an in-depth evaluation of the late-phase pipeline candidates as well as product specific assumptions and events impacting on marketed drugs sales forecasts to Published: Oct-06 Product code: DMHC2224 Commercial Insight: Top 20 Cancer Therapeutics New treatment paradigms transforming market outlook Analysis of the current and future potential of the cancer market in terms of the Top 20 leading therapeutics. Includes in-depth profiles and sales forecasts to 2015 across the seven major markets in light of key events to influence product revenues. Published: Jul-06 Product code: DMHC2182 Pipeline Insight: Non-Small Cell Lung Cancer Angiogenesis and signal transduction inhibitors to expand market and clinical opportunities Clinical and commercial assessment of late-stage pipeline cytotoxic and molecular-targeted treatments (MTT) for non-small cell lung cancer (NSCLC), including Datamonitor's assessment of their commercial potential and global sales forecasts to Published: Apr-06 Product code: DMHC2159 Pipeline/Commercial Insight: Innovative Targeted Therapies 'Smart Drugs' on target for increasing growth Analysis of the current and future potential of the targeted therapies market. Includes in-depth profiles of the late-phase pipeline, strategic recommendations and forecasts to 2014 for key products across the seven major pharmaceutical markets. Published: Oct-05 Product code: DMHC2112 For more information about our products visit Subscribe to Healthcare Monitor A monthly update of the latest Healthcare products, events, news and special offers from Datamonitor delivered to you by . To subscribe your contact details to hcmonitor@datamonitor.com with subscribe in the subject line.

12 Stakeholder Insight: Non-Small Cell Lung Cancer The Need for Greater Product Differentiation in an Increasingly Crowded Market DMHC2223 Place your order now... Fax back to (from Europe), (from the US) or (from Asia Pacific) I would like to order: Product title Product code Price / / $ / * * Please refer to our website for up-to-date prices Complete your details: Name Job Title Department Company Address State/Province Post Code/ZIP Country Tel Fax Sign below to confirm your order: Complete payment details: Please indicate your preferred currency option: UK Euro US$ Yen I enclose a check payable to Datamonitor plc for (+ p+p $30 UK / $60 rest of world) Please invoice my company for (+ p+p $30 UK / $60 rest of world) Please debit my credit/charge card Amex Visa Diners Mastercard Card No Expiry Date / Cardholder Signature Cardholder address Please supply purchase order number here if required by your accounts department: EU companies (except UK) must supply: VAT / BTW / MOMS / MWST / IVA / FPA number: Datamonitor products and services are supplied under Datamonitor s standard terms and conditions, copies of which are available on request. Payment must be received within 28 days of receipt of invoice. I do not want to receive future mailings from Datamonitor and its related companies. Occasionally, our client list is made available to other companies for carefully selected mailings. Please check here if you do not wish to receive such mailings. DMHC2223WEB From Europe: tel: fax: hcmarketing@datamonitor.com From the US: tel: fax: hcmarketing@datamonitor.com From Asia Pacific: tel: fax: apinfo@datamonitor.com Contact us to find out more about our products and services